Acl Clinical Trials
Here are the 6 most popular medical studies for acl
Nutritional Intervention
Omega-3 Fatty Acids and Essential Amino Acids for Muscular Atrophy
"This trial aims to investigate whether a combination of essential amino acids and omega-3 fatty acids can help prevent muscle loss and weakness after knee surgery. The study will involve participants taking these supplements before and after
Anti-metabolites
Paclitaxel +2 More for Peritoneal Neoplasm
The goal of this clinical research study is to learn about the safety and tolerability of paclitaxel and carboplatin when given in combination with Avastin to patients with ovarian, primary peritoneal, or fallopian tube cancer. Objectives: Primary study goals: To investigate the safety and tolerability of carboplatin and paclitaxel administered IP in combination with IV Avastin To determine if Avastin influences the pharmacokinetics of IP administered chemotherapeutic agents Secondary study goals: To determine the systemic exposure to paclitaxel and carboplatin during initial and late cycles of IP dosing. To collect overall survival (OS) and progression-free survival (PFS) To determine changes in IP VEGF levels To determine site of first recurrence Information on CA-125 response and clinical response will be descriptive as secondary goals of this study Exploratory goal: To estimate proportion of patients completing entire course of treatment
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Popular filter options for acl trials
Breast Cancer Clinical Trials
View 22 Breast Cancer medical studies.
mTOR Inhibitor
RAD001 +4 More for Breast Cancer
The goal of this clinical research is to learn if RAD001 given in combination with chemotherapy will turn off the signaling pathway (a chain of information that tells cancer cells to grow quickly) and make the chemotherapies given on this study more effective. Primary Objective · To determine if the addition of an mTOR inhibitor to standard neoadjuvant chemotherapy in patients with triple receptor-negative breast cancer causes molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway. Secondary Objectives To evaluate pathologic complete response (pCR) rates for each treatment group. To evaluate the relationship between pCR and the molecular changes (inhibition/activation) of the PI13K/PTEN/AKT pathway in each treatment group. To evaluate overall response rates (ORR) for each treatment group. To assess the toxicity of both regimens and to evaluate the relationship of toxicities with PI3K/PTEN/AKT pathway status.
Alkylating agents
Cyclophosphamide +3 More for Breast Cancer
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. Also, the study will look at whether there are gene expression profiles in the tumor tissue that can predict pathologic complete response.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
LABC Clinical Trials
View 22 LABC medical studies.
mTOR Inhibitor
RAD001 +4 More for Breast Cancer
The goal of this clinical research is to learn if RAD001 given in combination with chemotherapy will turn off the signaling pathway (a chain of information that tells cancer cells to grow quickly) and make the chemotherapies given on this study more effective. Primary Objective · To determine if the addition of an mTOR inhibitor to standard neoadjuvant chemotherapy in patients with triple receptor-negative breast cancer causes molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway. Secondary Objectives To evaluate pathologic complete response (pCR) rates for each treatment group. To evaluate the relationship between pCR and the molecular changes (inhibition/activation) of the PI13K/PTEN/AKT pathway in each treatment group. To evaluate overall response rates (ORR) for each treatment group. To assess the toxicity of both regimens and to evaluate the relationship of toxicities with PI3K/PTEN/AKT pathway status.
Alkylating agents
Cyclophosphamide +3 More for Breast Cancer
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. Also, the study will look at whether there are gene expression profiles in the tumor tissue that can predict pathologic complete response.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
HER2 Positive Clinical Trials
View 8 HER2 positive medical studies.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Monoclonal Antibodies
T-DM1 for Breast Cancer
This trialis testing a drug to see if it works to treat a specific cancer. It has been used in other studies but not yet approved by the FDA. It's being compared to existing treatments to see if it has less side effects and better long-term benefits.
Phase 3 Acl Clinical Trials
View 80 phase 3 acl medical studies.
Alkylating agents
Cyclophosphamide +3 More for Breast Cancer
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. Also, the study will look at whether there are gene expression profiles in the tumor tissue that can predict pathologic complete response.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Taxane
Paclitaxel +1 More for Fallopian Tube Cancer
This trial is studying paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial, peritoneal cancer, or fallopian tube cancer.
Acl Clinical Trials With No Placebo
View 80 acl medical studies that do not have a placebo group.
Stem Cell Therapy
Bio ACL Reconstruction for Anterior Cruciate Ligament Rupture
This trial is testing a new type of ACL surgery that uses a collagen-based membrane derived from amniotic tissue. The hope is that this will help the new ACL ligament to better heal and mature, allowing people to safely return to sports and other activities sooner.
mTOR Inhibitor
RAD001 +4 More for Breast Cancer
The goal of this clinical research is to learn if RAD001 given in combination with chemotherapy will turn off the signaling pathway (a chain of information that tells cancer cells to grow quickly) and make the chemotherapies given on this study more effective. Primary Objective · To determine if the addition of an mTOR inhibitor to standard neoadjuvant chemotherapy in patients with triple receptor-negative breast cancer causes molecular changes (inhibition/activation) of the PI3K/PTEN/AKT pathway. Secondary Objectives To evaluate pathologic complete response (pCR) rates for each treatment group. To evaluate the relationship between pCR and the molecular changes (inhibition/activation) of the PI13K/PTEN/AKT pathway in each treatment group. To evaluate overall response rates (ORR) for each treatment group. To assess the toxicity of both regimens and to evaluate the relationship of toxicities with PI3K/PTEN/AKT pathway status.
Alkylating agents
Cyclophosphamide +3 More for Breast Cancer
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxic effects of the chemotherapy combination, including effects on the heart, and will determine survival and progression-free survival 5 years after treatment. Also, the study will look at whether there are gene expression profiles in the tumor tissue that can predict pathologic complete response.
View More Acl Trials
See another 57 medical studies focused on acl.
Frequently Asked Questions
Introduction to acl
What are the top hospitals conducting acl research?
When it comes to cutting-edge clinical trials for the treatment of ACL (anterior cruciate ligament) injuries, several top hospitals are leading the way. In Burbank, California, Providence Saint Joseph Medical Center/Disney Family Cancer Center is at the forefront with nine active ACL trials. This hospital and research center, located in close proximity to the glitz and glamour of Hollywood, is making strides in advancing medical knowledge on this common sports-related injury. Moving across the country to Newark, Delaware, Christiana Care Health System-Christiana Hospital is also heavily involved in ACL research with eight ongoing trials. Serving as a major healthcare provider in Delaware and neighboring states, this institution plays a crucial role in understanding and improving treatments for athletes suffering from ACL injuries.
In Colorado Springs at Penrose-Saint Francis Healthcare, researchers are conducting seven active clinical trials focused on ACL injuries. This picturesque location nestled near the Rocky Mountains offers an ideal backdrop for exploring innovative approaches to treating these debilitating knee conditions. Meanwhile, Porter Adventist Hospital in Denver has also made significant contributions with seven ongoing acl trials.The bustling city of Denver provides an urban setting where medical professionals can collaborate on groundbreaking acl studies.
Not too far away lies Lakewood where Saint Anthony Hospital is actively engaged in seven current acl trials.As part of their commitment towards bettering public health by researching such critical areas; they have been steadily contributing through years continuing their consecutive participation over time
These hospitals may not have conducted any historical acl trails; however,the fact that they are undertaking multiple simultaneous studies highlights their dedication to finding new solutions for patients living with ACL injuries. By pushing boundaries and exploring novel approaches through these clinical trials ,these institutions aim bring long-lasting improvements to those who suffer from one of the most common sports-related knee ailments
Which are the best cities for acl clinical trials?
When it comes to ACL clinical trials, several cities emerge as leaders in research and development. Anchorage, Alaska leads the way with 43 active trials studying various treatments like Bevacizumab, Ramucirumab, and Quality-of-Life Assessment. Denver, Colorado closely follows with 37 ongoing studies focused on interventions such as Bevacizumab, Paclitaxel, and Trastuzumab. Lastly, Los Angeles offers a vibrant hub for ACL trials with 30 active studies exploring treatments like Paclitaxel, Bevacizumab, and Carboplatin. These cities provide individuals seeking innovative solutions for ACL issues access to cutting-edge clinical trials that can potentially enhance quality of life and advance treatment options.
Which are the top treatments for acl being explored in clinical trials?
Clinical trials are paving the way for innovative treatments in ACL (anterior cruciate ligament) injuries. One promising contender is platelet-rich plasma therapy, a non-surgical option that utilizes the patient's own blood to promote healing. Another potential treatment being explored is mesenchymal stem cell therapy, which involves injecting specialized cells into the damaged area to encourage tissue repair. Lastly, there are ongoing trials investigating the efficacy of bioabsorbable implants, which can provide mechanical support during recovery and gradually dissolve over time. With these advancements on the horizon, patients with ACL injuries may soon have more effective and personalized treatment options available to them.
What are the most recent clinical trials for acl?
Exciting developments in ACL research are shedding light on potential breakthroughs for treatment. One notable clinical trial involves a combination of ACL repair, Exparel, and nerve block therapy. The aim is to assess the effectiveness of this approach in promoting successful outcomes post-surgery. Additionally, another study explores the use of Zoledronic Acid Injection as a possible intervention for ACL injuries. Furthermore, researchers are investigating the efficacy of an iNOS inhibitor and nab-paclitaxel in conjunction with alpelisib for treating ACL patients. Another trial examines VCN-01 combined with standard care treatments to determine its impact on patient recovery and rehabilitation following an ACL injury. Lastly, Linaclotide is being evaluated in a Phase 3 study to gauge its potential benefits for individuals with ACL issues. These trials offer hope for improved management strategies and enhanced quality of life among those affected by ACL injuries.
What acl clinical trials were recently completed?
Recent advancements in the field of ACL research have led to the completion of several important clinical trials. These studies focused on evaluating new treatments and techniques for addressing anterior cruciate ligament (ACL) injuries. While specific details may vary, these recent completed trials highlight the continued efforts of researchers to improve outcomes and enhance rehabilitation strategies for individuals with ACL tears.